Pamela Burian
Physician Assistant · Los Angeles, CANPI 1942210893
Payments from drug & device makers
Across 174 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- Viiv Healthcare Company$1K
- Merck$622
- Johnson & Johnson$455
- EMD Serono, Inc.$226
- Theratechnologies Inc.$160
- plus $240 from 6 others
What the payments were for
- Food & beverage$4,05995%
- Education$1975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 39 | $1,297 |
| Viiv Healthcare Company | 53 | $1,257 |
| Merck | 28 | $622 |
| Johnson & Johnson(2 entities) | 29 | $455 |
| EMD Serono, Inc. | 11 | $226 |
| Theratechnologies Inc. | 7 | $160 |
| Janssen Products, LP | 1 | $100 |
| Exact Sciences | 2 | $43 |
| GSK | 1 | $28 |
| AbbVie | 1 | $27 |
| Lilly USA, LLC | 1 | $23 |
| Bausch Health US, LLC | 1 | $18 |
How this compares
$4,256 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 964 | $3,749,498 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 130 | $467,509 |
| TasignaNilotinib Hcl | 13 | $235,917 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 34 | $163,562 |
| JulucaDolutegravir/Rilpivirine | 35 | $117,671 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $110,492 |
| TrulicityDulaglutide | 93 | $94,015 |
| TivicayDolutegravir Sodium | 32 | $69,951 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 18 | $69,285 |
| DescovyEmtricitabine/Tenofov Alafenam | 29 | $61,900 |
| DovatoDolutegravir Sodium/Lamivudine | 19 | $54,968 |
| OzempicSemaglutide | 44 | $40,819 |
| PrezcobixDarunavir/Cobicistat | 17 | $38,146 |
| SynjardyEmpagliflozin/Metformin Hcl | 58 | $34,387 |
| JardianceEmpagliflozin | 43 | $24,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,297 | $3,880,6831,011 claims |
| Viiv Healthcare CompanyTriumeq, Juluca, Cabenuva, Tivicay, Dovato | $1,257 | $820,591234 claims |
| Janssen Products, LPSymtuza | $100 | $163,56234 claims |
| Lilly USA, LLCTrulicity | $23 | $94,01593 claims |
| Johnson & JohnsonPrezcobix | $455 | $38,14617 claims |
| MerckJanuvia, Janumet | $622 | $25,33540 claims |
| GSKBreo Ellipta, Shingrix | $28 | $8,48328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Los Angeles
- Eric CheungLos Angeles$213K
- Asia SullivanLos Angeles$61K
- Felipe FindleyLos Angeles$51K
- Melissa GriffinLos Angeles$39K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.